Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-05-22
2007-05-22
Carlson, Karen Cochrane (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
10724833
ABSTRACT:
This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.
REFERENCES:
patent: 5324821 (1994-06-01), Favre et al.
patent: 6087325 (2000-07-01), Meers et al.
patent: 6245753 (2001-06-01), Byun et al.
patent: 6288040 (2001-09-01), Muller et al.
patent: 0 277 849 (1988-08-01), None
patent: WO 87/02061 (1987-04-01), None
patent: WO 92/21330 (1992-12-01), None
patent: WO 98/13385 (1998-04-01), None
patent: WO 99/04761 (1999-02-01), None
Westesen et al., Characterization of native and Drug-Loaded Human Low Density Lipoproteins, J. of Pharmaceutical Sciences, (1995) 84(2), p. 139-147.
Versluis et al., Stable Incorporation of a Lipophilic Danorubicin Prodrug into Apolipoprotein E-Exposing Liposomes Induces Uptake of Prodrug via Low-Density Lipoprotein Receptor in Vivo, J. of Pharmacology and Exp. Therap., (1999) 289(1), p. 1-7.
Rensen et al. “Human Recombinant Apolipoprotein E-Enriched Liposomes Can Mimic Low-Density Lipoproteins as Carriers for the Site-Specific Delivery of Antitumor Agents.” Molecular Pharmacology 52:445-455, Sep. 1997 XP-002273272.
Kreuter et al., “Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier.” Journal of Drug Targeting, 2002 vol. 10(4) pp. 317-325, Xp009027368.
Versluis et al., “Synthesis of a Lipophilic Daunorubicin Derivative and Its Incorporation inot Lipidic Carriers Developed for LDL Receptor-Mediated Tumor Theraphy.” Pharmaceutical Reasearh, vol. 15, No. 4, 1998, XP009036781.
Masquelier et al., “Low Density Liproprotein as a Carrier of Cytostatics in Cancer Chemotherapy: Study of Stability of Drug-Carrier Complexes in Blood.” Journal of Drug Trageting, 2000, vol. 8, No. 3, pp. 155-164, XP009027575.
Masquelier et al., “Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins.” Eur. J. Med. Chem. 35 (2000) 429-438.
Murtha et al., “Synthesis of the Cholesteryl Ester Prodrugs Cholesteryl Ibuprofen and Cholesteryl Flufenamate and Their Formulation into Phospholipid Microemulsions,” 1088 Journal of Pharmaceutical Sciences, 83 (1994) Sep., No. 9, DC. US, XP 00465804.
Rensen et al., “Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.” Advanced Drug Delivery Reviews 47 (2001) 251-276, XP-002273271.
Bhattacharya et al., “Novel distamycin analogues: facile synthesis of cholesterol conjugates of distamycin-like oligopeptides.” Tetrahedron Letters 42 (2001) 3499-3502, XP-002299552.
Reinhardt, R.R. et al., “Insulin-Like Growth Factors Cross the Blood-Brain Barrier,” Endocrinology, vol. 135, No. 5.
Witt, Ken A. et al., “Insulin Enhancement of Opioid Peptide Transport across the Blood-Brain Barrier and Assessment of Analgesic Effect,” The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 3, 3100/866639.
Rigotti, Attilio et al., “The Class B Scavenger Receptors SR-BI and CD36 Are Receptors for Antonic Phospholipids,” The Journal of Biological Chemistry, vol. 270, No. 27, Issue of Jul. 7, pp. 16221-16224, 1995.
Bradley, William et al., “Low-density Lipoprotein Receptor Binding Determinants Switch from Apolipoprotein E to Apolipoprotein B during Conversion of Hypertriglyceridemic Very-low-density Lipoprotein to Low-density Lipoproteins,” The Journal of Biological Chemistry, vol. 259, No. 23, Issue of Dec. 10, pp. 14728-14735, 1984.
Veingergs, Isaac et al., “Neurotoxic Effects of Apolipoprotein E4 are Mediated via Dysregulation of Calcium Homeostasis,” Journal of Neuroscience Research 67:379-387 (2002).
Shibata, Masayoshi et al., “Clearance of Alzheimer's amyloid-B1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier,” The Journal of Clinical Investigation, Dec. 2000, vol. 106, No. 12.
Alyaudtin, Renad et al. “Interaction of Poly(butylcyanoacrylate) Nanoparticles with Blood-Brain Barrier in vivo and in vitro,” Journal of Drug Targeting, 2001, vol. 9, No. 3, pp. 209-221.
Kang, Young-Sook et al., “Stability of the Disulfide Bond in an Avidin-Biotin Linked Chimeric Peptide During in vivo Transcytosis Through Brain Endothelial Cells,” Journal of Drug Targeting, 2000, vol. 8, No. 6, pp. 425-434.
Pardridge, William M., “CNS Drug Design Based on Principles of Blood-Brain Barrier Transport,” J. Neurochem., vol. 70, No. 5, 1998.
Bickel, Ulrich et al., “Delivery of peptides and proteins through the blood-brain barrier,” Advanced Drug Delivery Reviews, 10 (1993) 205-245.
Hevonoja, Tiia et al., “Structure of low density lipoprotein (LDL) particles: Basis for understanding molecular changes in modified LDL,” Biochemica et Biophysica Acta 1488 (2000) 189-210.
Pardrige, William M. et al., “Blood-Brain Barrier: Interface Between Internal Medicine and the Brain,” Annals of Internal Medicine, 1986; 105: 82-95.
Wu, Dafang et al., “Pharmacokinetics and Brain Uptake of Biotinylated Basic Fibroblast Growth Factor Conjugated to a Blood-Brain Barrier Drug Delivery System,” Journal of Drug Targeting, 2002 vol. 10(3), pp. 239-245.
Mims, Marth P. et al., “Effect of Particle Size and Temperature on the Conformation and Physiological Behavior of Apolipoprotein E Bound to Model Lipoprotein Particles,” Biochemistry 1990, 29, 6639-6647.
Hotlzman, David M., “Role of apoE/AB Interactions in the Pathogenesis of Alzheimer's Disease and Cerebral Amyloid Angiopathy,” Journal of Molecular Neurosciences, vol. 17, 2001, pp. 147-155.
Xu, J. et al., “Tissue-specific regulation by vitamin D3 of a novel protein containing ankyrin-like repeats,” Molecular and Cellular Endocrinology, Jan. 3, 1997, vol. 126, No. 1, pp. 101-107, XP0009027368.
Alkon Daniel
Nelson Thomas
Quattrone Alessandro
Carlson Karen Cochrane
Milbank Tweed Hadley & McCloy LLP
Rooke Agnes B.
LandOfFree
Artificial low-density lipoprotein carriers for transport of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Artificial low-density lipoprotein carriers for transport of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Artificial low-density lipoprotein carriers for transport of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3727474